Table 1. Features of the patients at diagnosis.
| Variable | Value |
|---|---|
| Gender (for all 103 cases) | |
| Male | 56 |
| Female | 47 |
| Age in years (median, range) | 42 (8-81) |
| Sokal score (100 cases) | |
| Low risk | 30 |
| Intermediate risk | 42 |
| High risk | 28 |
| Hasford score (100 cases) | |
| Low risk | 67 |
| Intermediate risk | 27 |
| High risk | 6 |
| EUTOS score (99 cases) | |
| Low risk | 92 |
| Intermediate risk | 7 |
| Treatment before imatinib (no. Patients) | |
| Hydroxyurea | 103 |
| Interferon-α | 34 |
| Median interval diagnosis - start imatinib (days) | 99 (27-1780) |
| For patients in early chronic phase (days) | 60 |
| For patients in late chronic phase (days) | 963 |
| Years in school | 4 (0-17) |
| Median income per family member and month (in R$)* | 226.00 (9.00-3,000.00) |
| Distance from the home to the hospital (in km) | 150 (1-794) |
These values correspond to a mean of 1 Real=0.5 US$ during the study period